Savient Pharmaceuticals posts $212,165 net loss, zero revenue in April

By Kali Hays

New York, May 7 - Savient Pharmaceuticals, Inc. reported a $212,165 net loss for the period between March 29 and April 24 on zero revenue, according to its monthly operating report filed Wednesday with the U.S. Bankruptcy Court for the District of Delaware.

Those numbers compare to a net loss of $2.7 million on net revenue of $8,294 for its March period.

The company also reported $668,972 in cash and equivalents as of April 24, a marked decline from $11.03 million reported as of March 28.

Savient, an East Brunswick, N.J., pharmaceutical company, filed for bankruptcy on Oct. 15, 2013. The Chapter 11 case number is 13-12680.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.